Results 61 to 70 of about 12,926,306 (256)

Supplementary Figure S6: Ipilimumab does not deplete CD4+CTLA-4+FOXP3+ Tregs from Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers

open access: yes, 2019
Tumor infiltrating cells from paired melanoma tissue (N=5 pre-Ipi; N=5 post-Ipi) were analyzed by CyTOF. The impact of ipilimumab on the intratumoral frequency of A) CD3+CD4+FOXP3+CTLA-4+ (Tregs), B) CD3+CD4+FOXP3-CTLA-4+ T cells, and C) CD3+CD4+FOXP3 ...
Padmanee Sharma (8133285)   +8 more
core   +1 more source

Supplementary Data from Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs

open access: yes, 2022
Supplementary Data from Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited ...
Andrew Sharabi (3158010)   +15 more
core   +1 more source

Single‐Dose TACE‐Like Injection of Sustained‐Release Panobinostat/IL‐12 Polymeric Microparticles is Effective in Preclinical Liver Cancer Models

open access: yesAdvanced Science, EarlyView.
A novel PLGA/PBAE polymer microparticle platform revolutionizes intermediate‐stage liver cancer treatment by co‐delivering panobinostat and IL‐12 via a single TACE‐like injection. This sustained‐release system overcomes tumor immunosuppression, triggers robust innate and adaptive immune responses, and establishes tertiary lymphoid structures ...
Hongzhe Yu   +7 more
wiley   +1 more source

Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the cis CD80/PD-L1 interaction

open access: yesCell Reports
Summary: The CTLA-4 and PD-1 checkpoints control immune responses and are key targets in immunotherapy. Both pathways are connected via a cis interaction between CD80 and PD-L1, the ligands for CTLA-4 and PD-1, respectively. This cis interaction prevents
Maximillian A. Robinson   +11 more
doaj   +1 more source

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy

open access: yesCellular Physiology and Biochemistry, 2018
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a membrane glycoprotein expressed by activated effector T cells (Teffs) and participates in the repression of T cell proliferation, cell cycle progression and cytokine production.
Yinghao Zhao   +5 more
doaj   +1 more source

Related Article from Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity

open access: yes, 2013
Related Article from Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding ...
Holbrook Kohrt (3541958)   +2 more
core   +1 more source

CTLA-4 gene polymorphisms are associated with obesity in Turner syndrome [PDF]

open access: yes, 2018
Turner syndrome (TS) is characterized by a set of clinical conditions, including autoimmune/inflammatory diseases and infectious conditions, that can compromise a patient's quality of life.
Sergio Crovella (290351)   +41 more
core   +1 more source

Macrophage PABPC4‐SPP1 Axis Orchestrates Immunosuppression in Colorectal Cancer

open access: yesAdvanced Science, EarlyView.
In the CRC microenvironment, macrophage PABPC4 binds to the 3′UTR of SPP1 mRNA to stabilize its expression, thereby sustaining M2‐like immunosuppressive macrophage polarization. Concurrently, this axis suppresses CD8+ T cell effector functions via CD44 signaling, collectively fostering an immunosuppressive niche that drives tumor progression.
Meng Wang   +14 more
wiley   +1 more source

Correlation Between IFNγ+ and CTLA-4+ Tumor Infiltrating Lymphocytes In Luminal And Non-Luminal Breast Carcinoma

open access: yesQanun Medika: Jurnal Kedokteran Fakultas Kedokteran Universitas Muhammadiyah Surabaya, 2019
The role of tumor infiltrating lymphocytes (TIL) in breast carcinoma depends on the molecular subtype, especially the expression of the estrogen receptor.
Irene Lingkan Parengkuan   +2 more
doaj   +1 more source

CTLA-4 expression, regulation and associations in autoimmune myasthenia gravis

open access: yes, 2003
Myasthenia gravis (MG) is a neuromuscular disease with muscle weakness due to an autoimmune attack against the nicotinic acetylcholine receptor (nAChR) on the skeletal muscle endplate.
XiongBiao Wang (19494277)
core   +1 more source

Home - About - Disclaimer - Privacy